Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 4/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.74 |
| ▸ | HTT | P42858 | 3/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL1159786 | 0.98 | PKM (0.72) | PKMALDH1A1HTTPOLBLMNA | |
| SCHEMBL1956663 | 0.97 | ALDH1A1 (0.70) | PKMALDH1A1HTTPOLBLMNA | |
| SCHEMBL3111901 | 0.94 | ALDH1A1 (0.76) | PKMALDH1A1HTTPOLBLMNA | |
| Aziridine SCHEMBL22778235 | 0.93 | KMT2A (0.76) | PKMALDH1A1HTTPOLBLMNA | |
| SCHEMBL1259378 | 0.92 | PKM (0.69) | PKMALDH1A1HTTPOLBLMNA | |
| SCHEMBL3976265 | 0.92 | PKM (0.69) | PKMALDH1A1HTTPOLBLMNA | |
| SCHEMBL651924 | 0.89 | MAPT (0.69) | PKMALDH1A1HTTPOLBLMNA | |
| SCHEMBL5955341 | 0.89 | MAPT (0.69) | PKMALDH1A1HTTPOLBLMNA | |
| SCHEMBL9122576 | 0.89 | MAPT (0.69) | PKMALDH1A1HTTPOLBLMNA | |
| SCHEMBL4109280 | 0.88 | CD4 (0.60) | PKMALDH1A1HTTPOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111170953-A | Process for preparing diazacyclooctane intermediates and diazacyclooctanes | 郑州手性药物研究院有限公司 | 2020-05-19 | — | — | CN | claimed |
| US-20240124400-A1 | LPXH TARGETING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME | DUKE UNIVERSITY (US) | 2024-04-18 | — | — | US | disclosed |
| WO-2021072369-A1 | LPXH TARGETING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME | DUKE UNIVERSITY (US) | 2021-04-15 | — | — | WO | disclosed |
| CN-111170953-A | Process for preparing diazacyclooctane intermediates and diazacyclooctanes | 郑州手性药物研究院有限公司 | 2020-05-19 | — | — | CN | disclosed |
| CN-111170953-A | Process for preparing diazacyclooctane intermediates and diazacyclooctanes | 郑州手性药物研究院有限公司 | 2020-05-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124400-A1 | LPXH TARGETING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME | CFH, LPAR3, CBR3 | PKM 4576/4885ALDH1A1 3931/4885HTT 2865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.